Are you posting this as a general caveat on the upcoming Phase 2b data for 011? Or are you posting this to show how difficult this patient population is to treat and how meaningful any kind of response from 011 could be? And I'd be curious to know if the Phase 2a trial had patients that had a median number of 7 preceding treatments as well (wherein CLDX saw what I think could be deemed promising results).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.